Castleman disease (CD) is a rare lymphoproliferative disorder. To assess the clinical features, outcomes, and prognostic factors of this disease, we retrospectively analyzed 185 HIV-negative CD patients from four medical centers in southern China.
| INTRODUCTION
Castleman disease (CD), also known as angiofollicular or giant lymph node hyperplasia, is a rare non-neoplastic lymphoproliferative disorder that was first described in 1956. 1 According to the lesions involved, CD can be characterized as unicentric (UCD) or multicentric (MCD). Unicentric CD is typically localized, indolent, and often treated with localized therapy alone. In contrast, MCD is a systemic condition associated with heterogeneous symptoms and is usually treated with systemic therapies. Histologically, CD can be classified into 3 types: hyaline-vascular, plasma cell, and mixed cellular. The hyaline-vascular type is more common in UCD patients; in contrast, the plasma cell type is more common in MCD. 2 Although the etiology of CD is unclear, a large body of evidence
shows that IL-6 plays a pivotal role in the development of CD, especially of MCD. 3 Recent data also suggested that MCD is associated with HHV-8, 3 ,4 the same virus found in Kaposi's sarcoma, which encodes a structural and functional homolog of human IL-6 called viral IL-6. Human herpes virus 8 is often identified in CD patients with HIV, 5 but it is also present in some HIV-negative cases. Additionally, of all published cases of MCD, more than one-third are negative for both HHV-8 and HIV. 6 The cause of this type of idiopathic MCD is poorly understood.
As CD is a rare disease, current studies are mostly retrospective or case reports from single institutions and the clinical characteristics, optimal treatments, and prognosis of CD remain controversial.
In addition, HIV status is considered to be an important prognostic factor of CD, 7, 8 and recent studies have paid more attention to HIVpositive MCD. [9] [10] [11] [12] Consequently, data on HIV-negative CD patients are limited. Here we retrospectively analyzed 185 HIV-negative CD patients from 4 large medical institutions in southern China, to better understand the characteristics, outcomes, and prognostic factors of this disease. To the authors' knowledge, this study comprises the largest sample size currently analyzed. Independent prognostic factors were determined by having a significant effect in the Cox model (P < .05). 3 | RESULTS
| MATERIALS AND METHODS

| Ethics approval and consent to participate
| Clinical features
The clinical characteristics of 185 HIV-negative CD patients are shown in Table 1 . The ratio of male to female patients was 
| Treatment and survival of CD patients
All 121 UCD patients underwent primary lesion resections alone. For the 64 MCD patients, the treatment modalities are shown in Table 3 .
Seventeen asymptomatic patients without complications received a "watch and wait" strategy. They were followed up regularly every 3-6 months. Five patients underwent surgery and 6 patients who could The median follow-up for all CD patients was 50 months (range, 2-161 months). By the date of the last follow-up, 30 deaths occurred (38.6%), of which 27 patients died of tumor progression and 3 died due to the treatment; 6 patients were UCD and 24 patients were MCD. The 5-year OS was 80.3% ( Figure 1 ). For UCD patients, the 5-year OS and DFS were 93.6% and 91.2%, respectively (Figures 2 and 3) . For MCD patients, the 5-year OS was 51.2% ( Figure 2 ). The log-rank test for OS showed a statistically significant difference between UCD and MCD patients (P < .001). Table 4 .
T A B L E 2 Comparison of clinical characteristics between patients with unicentric (UCD) and multicentric (MCD) Castleman disease
Multivariate analysis using a Cox proportional hazards regression model showed that age, splenomegaly, and serum albumin level were independent factors for OS in MCD patients (Table 5 , Figure 4 ).
| DISCUSSION
Because of its rarity, our understanding of CD is mainly from retrospective studies and case reports. Only a few studies have focused on the prognostic factors of CD, especially in HIV-negative patients.
To better understand this disease, we presented a large series of CD patients from southern China in this multicenter study. Notably, our study comprises the largest sample size analyzed to date.
According to previous studies, HIV infection is an important factor in the pathogenesis of CD and strongly influences the prognosis. 7, 8, 10 Previous studies with relatively large cohorts have presented high-quality data regarding HIV-positive CD patients, [9] [10] [11] [12] but few reports have focused on HIV-negative patients. [15] [16] [17] The prevalence of HIV in China is very low. 18 All the CD patients included in our study were proven to be HIV-negative. The present UCD and MCD is confirmed in our study. Consistent with previous studies, 16, 17, 19 our study found that UCD cases were more common than MCD. For the UCD group, patients were younger (median age, 33 years) and most cases were asymptomatic. The most common histological type of UCD was the hyaline-vascular variant, accounting for 91.7% of UCD cases, similar to previous studies. 16, 17, 19 Compared with the UCD group, our MCD patients were older (median age, 42 years) and appeared to be more symptomatic. Plasma cell variant cases were also more common in the MCD group. Other complications such as splenomegaly, ascites, pleural effusion, and POEMS syndrome also occurred more frequently in MCD patients.
For UCD, complete resection of the involved lesion is considered the gold standard treatment 20 and is curative in almost all cases reported so far, with a 5-year OS rate approaching 100%. [21] [22] [23] For patients whose tumor mass is unresectable because of size or location, radiotherapy can be utilized to reduce tumor size. 24, 25 In our study, all 121 UCD patients received primary lesion resection alone as the initial treatment and the outcome was excellent, with the 5-year DFS rate and OS rate being 91.2% and 93.6%, respectively.
Unlike UCD, the optimal treatment for MCD has not been well established and the outcome is less favorable. In our study, MCD patients had significantly worse survival rates compared with UCD patients, with the 5-year OS rate being 51.2% (P < .001). These results were consistent with previous reports. arm study. 35 Siltuximab, a humanized anti-IL6 mAb, was approved for idiopathic MCD in the USA, Canada, and Europe, based on data from a double-blind, placebo-controlled, phase II trial showing significantly higher durable tumor response and symptomatic response compared with placebo (P = .0012). 36 In our study, more than half of MCD patients received corticosteroids or cytotoxic chemotherapy as first-line therapy. However, the treatments given to these patients were quite heterogeneous and few patients received new agents such as anti-IL-6 antibody and rituximab. Therefore, we were unable to identify the optimal treatment strategy for MCD in this study.
Due to the lack of optimal treatment for MCD, it is important to identify prognostic factors to help determine treatment strategies.
However, no generally accepted prognostic factors of MCD have been found because of the low incident of CD and limited sample size of each study. In the present study, univariate and multivariate analysis identified older age, splenomegaly, and hypoalbuminemia as independent prognostic factors of MCD patients.
Older age has been widely reported to be a negative risk factor for various lymphoproliferative diseases, including Hodgkin's and non-Hodgkin's lymphomas. Consistent with our findings, Dong et al 14 showed that CD patients aged more than 40 years had a poorer prognosis. A metaanalysis by Talat et al 17 also identified age as prognostic factor of HIVnegative CD patients by univariate analysis. Mantovani et al 37 found
that serum levels of IL-6 were significantly higher in elderly cancer patients. Considering IL-6 is related to the pathogenesis of CD, the poorer prognosis of older MCD patients may be due to increased IL-6 levels, which should be confirmed by further investigations.
In previous studies, splenomegaly was reported to be a common symptom of MCD patients, with a frequency ranging from 30% to 72%. 13, 16, 38, 39 In our study, the frequency of splenomegaly was 36%
and both univariate and multivariate analyses indicated that splenomegaly had a significant negative impact on MCD prognosis. Shin et al 16 suggested that the DFS of MCD patients with splenomegaly was significantly worse than those without splenomegaly. Similarly, splenomegaly was also identified by previous studies as a predictable risk factor for some types of lymphoma. 40, 41 We hypothesize that some MCD patients with splenomegaly have true splenic involvement, which may suggest a more aggressive disease and cause the poorer prognosis. However, this hypothesis could not be further confirmed in our study because none of our patients with splenomegaly underwent a spleen biopsy.
Serum albumin level has been widely reported to be a prognostic factor of solid malignancies [42] [43] [44] and several hematological malignancies. [45] [46] [47] [48] In the present study, hypoalbuminemia was found in 48.4%
MCD patients and was associated with poorer OS. We suggest that serum albumin level is not only a reflection of the general condition of MCD patients, but is also a powerful factor for predicting patient prognosis. Therefore, it should be closely monitored in clinical practice.
Recently, 2 other large-scale studies identified renal function and PNP as independent prognostic factors of MCD. 14, 15 However, these findings were not consistent with ours.
Previous data suggested that HHV-8 is present in 100% of HIVinfected MCD patients and in 40%-50% of HIV-negative cases. 49 Consistent with another report from Korea, 16 our study showed that the prevalence of HHV-8 infection in patients from southern China with MCD is 39.3%, much higher than that in UCD patients (8.1%).
This result helps to confirm the important role of HHV-8 in the pathogenesis of MCD, which has been well established by previous studies. 3, 4 Recent data also suggested that HHV-8 status may be associated with the prognosis of MCD, 16, 39 but the clinical evidence was limited. In this study, we failed to identify HHV-8 as a F I G U R E 4 Prognostic factors for overall survival in patients with multicentric Castleman disease. A, Overall survival (OS) according to age. B, OS according to serum albumin levels (Alb). C, OS according to splenomegaly prognostic factor for MCD due to limited sample size. Of note, although the prevalence is low, positive HHV-8 status can also be found in UCD cases. However, the role of HHV-8 in these UCD cases is unknown. Therefore, the potential association between HHV-8 and CD requires further verification.
A new disease concept characterized by thrombocytopenia, anasarca including pleural effusion and ascites, fever, renal dysfunction, and organomegaly, known as TAFRO syndrome, was first described by Takai et al 50, 51 The 
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